Humana's stock dipped by over 2% in premarket trading on Wednesday after the health insurer reiterated its adjusted full-year profit outlook of at least $9 per share. The company also cut its non-adjusted earnings forecast to at least $8.36 a share, down from a previous estimate of at least $8.89 a share. This downward revision accounts for charges related to a multi-year transformation program aimed at realigning its cost structure, operating model, and technology. Despite this, Humana reported a 23% jump in first-quarter revenue and beat adjusted earnings per share expectations.
Humana's challenges stem from higher medical and pharmaceutical costs, increased utilization of services, and reduced reliability of its Medicare Advantage program due to tighter government oversight and more restrictive payment policies. The company's diminished Medicare Advantage Star Ratings for 2026 are also pressuring bonus payments, with the federal government announcing only a 0.09% increase in Medicare Advantage payments for 2027, far below the anticipated 4% to 6% growth. This led to a significant 21.13% drop in Humana's stock on Tuesday.
Procter & Gamble reported a mixed second quarter for fiscal year 2025. The consumer products giant met Wall Street's revenue expectations with sales up 1.7% year-over-year to $20.89 billion. Its adjusted earnings per share of $1.48 surpassed analyst estimates of $1.42, a 4.1% beat. However, its EBITDA missed expectations, and its gross margin fell slightly short. Shares remained flat at $158.42 immediately following the announcement.
Key metrics for Procter & Gamble included a free cash flow margin of 19.1%, down from 24.2% in the prior year, and organic revenue growth of 2% year-on-year. Sales volumes remained flat. The company's CEO, Jon Moeller, highlighted strong sales and profit growth, and high levels of cash returned to shareholders amidst a dynamic and volatile environment.
